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Regulation of growth-hormone-receptor gene expression by
growth hormone and pegvisomant in human mesangial cells.
Background. Mice transgenic for growth hormone develop
mesangial proliferation, glomerular hypertrophy, and progres-
sive glomerular sclerosis suggesting that the growth hormone–
insulin-like growth factor I (IGF-I) pathway plays an important
role. Therefore, we studied the impact of variable concentra-
tions of 22 kD, 20 kD growth hormone, as well as of the growth
hormone receptor antagonist pegvisomant (B2036-PEG), on
both the growth hormone receptor (GHR/GHBP) gene expres-
sion and growth hormone binding protein (GHBP) formation
in a human glomerular mesangial cell line. Further, the impact
on collagen, IGF-I and IGF binding protein-1 (IGFBP-1) for-
mation was studied.
Methods. In order to assess transcription, quantitative reverse
transcription-polymerase chain reaction (RT-PCR) was used.
Results. Physiologic doses of 22 kD or 20 kD growth hormone
caused a dose-dependent and significant (P  0.01) up-regula-
tion of GHR/GHBP gene transcription, whereas supraphysio-
logic doses (50 and 500 ng/mL) resulted in down-regulation
(P  0.001). Whenever pegvisomant was used, there was no
increase in GHR/GHBP expression. These data were confirmed
using run-on experiments. Further, the assessment of GHBP
presented a constant, dose-dependent increase, which was com-
pletely abolished in the experiments where pegvisomant was
used.
Conclusion. We present data showing that growth hormone
has a direct impact on GHR/GHPB gene transcription and that
pegvisomant is a potent growth hormone receptor antagonist in
human mesangial cells. In addition, although the GHR/GHBP
gene transcription is down-regulated by supraphysiologic
growth hormone concentrations, this effect was not found when
GHBP levels were measured. This finding may reflect a self-
inhibitory effect of growth hormone on the level of GHR/
GHBP gene transcription, which does not involve the regula-
tion of the shedding of GHBP and may, therefore, be of physio-
logic interest.
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Glomerular hypertrophy and/or hyperplasia in experi-
mental renal diseases in rodents have been implicated
as a cause of progressive glomerular sclerosis and chronic
renal failure [1]. However, although the precise mecha-
nisms involved in the development of glomerulosclerosis
have not been fully elucidated, the growth hormone–
insulin-like growth factor-I (IGF-I) axis, including its
autocrine activation of signaling pathways, as well as
IGF-binding protein-1 (IGFBP-1), are suspected to play
an important role for several reasons [1–12]. First, mice
transgenic for either bovine or human growth hormone
expressing elevated growth hormone levels present a
giant phenotype, develop mesangial proliferation, glo-
merular hypertrophy, and progressive glomerular sclero-
sis, leading to renal failure and death by 8 to 9 months
of age [1, 13, 14]. Second, in the aging rats, there is a
strong correlation between the severity of glomerular
sclerosis and plasma growth hormone levels [15]. Third,
there are reports indicating that glomerulosclerosis may
be associated with acromegaly, suggesting that the over-
production of growth hormone may be partly responsible
for the development of human glomerulosclerosis [16, 17].
In addition, as compensatory renal growth in uninephrec-
tomized adult mice seems to be growth hormone–depen-
dent, growth hormone–deficient rats are somewhat pro-
tected from the development of glomerular sclerosis after
partial nephrectomy [18, 19]. Moreover, in streptozotocin-
induced diabetes in the rat, renal growth hormone recep-
tor (GHR) mRNA levels were found to be increased,
leading to speculation that the increased concentration
of growth hormone in circulation and, therefore, its ac-
tion may contribute to diabetic glomerulosclerosis [20].
Further, in dwarf mice transgenic for a mutated growth
hormone form (G119K), which acts as an antagonist of
endogenous growth hormone, glomeruli were reported
to be normal and these mice were protected from strep-
tozotocin-diabetes–induced progressive glomerular scle-
rosis [21, 22]. Increased growth hormone, as well as IGF-I
activity, is associated with increased glomerular produc-
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tion of extracellular matrix proteins, and the glomerular
lesions might resemble diabetic nephropathy [1, 23, 24].
As an extensive body of evidence supports the permis-
sive role of growth hormone in the development of glo-
merulosclerosis and experimental evidence suggests that
different domains of the growth hormone molecule
(mice transgenic for 20 kD and 22 kD growth hormone)
may cause variable effects on linear growth and/or organ
hypertrophy but an identical effect on the development
of glomeruscloeris [25], the aim of our study was to
analyze the impact of variable concentrations of 22 kD,
20 kD growth hormone, and of the GHR antagonist peg-
visomant (GHR-A; B2036-PEG) (Sensus Corp., Austin,
TX, USA) on the GHR/growth hormone binding protein
(GHR/GHBP) gene expression as well as on the GHBP
formation in a human glomerular mesangial cell line in
order to define the direct effect of growth hormone on
the regulation of the expression of its own receptor.
Further, the impact of growth hormone, growth hormone
variant, and GHR-A on types I and IV collagen, IGF-I
and IGFBP-1 secretion into the cell culture medium was
studied.
METHODS
Cell culture, mutant growth hormones, and
pegvisomant (B2036-PEG)
Following double transfection of human mesangial
cells (HMC) with T-SV40 and H-ras oncogene, stable
cell lines of T-SV40 immortalized human glomerular
mesangial (T-HMC) cells were obtained [26]. As these
cells do express the GHR, functional studies on the GHR/
GHBP gene expression can be performed. T-HMC were
maintained in monolayer culture as previously described
[26]. When they had reached approximately 70% con-
fluency, the medium was aspirated, the cells were washed
twice with phosphate-buffered saline (PBS), pH 7.4
(Sigma Chemical Co., St. Louis, MO, USA), and 1 mL
of a serum-free hormonally defined medium was added.
Serum-free hormonally defined medium contained 0.4
mmol/L ornithine; 2.25 g/mL l-lactic acid; 2 ng/mL
glucagon; 2.5  108 mol/L selenium; 5  108 mol/L
hydrocortisone; 1  106 mol/L ethanolamine; 2 ng/mL
choleratoxin; 1 g/mL insulin, 1 g/mL transferrin, 25
ng/mL endothelial growth factor (EGF) but, as pre-
viously reported, no growth hormone, IGF-I, IGF-II, or
IGFBP-1 [27]. After overnight incubation, the medium
was aspirated and the cells were washed twice with PBS
(pH 7.4). Thereafter, different samples containing vari-
able forms of growth hormone (22 kD, 20 kD growth
hormone) and pegvisomant were added to the culture
medium at various concentrations (12.5, 25, 50, and 500
ng/mL of growth hormone variants and, in pegvisomant
studies, an additional experiment using 20 g/mL pegvi-
somant was performed) and incubation was continued
for 0, 1, 3, or 6 hours. The additional dose of 20 g/mL
of pegvisomant was chosen with reference to a clinical
trial [28] in which, due to the reduced affinity of pegviso-
mant for the GHR compared to 22 kD growth hormone,
patients were treated for acromegaly with a standard
dose of 20 mg pegvisomant/ day and were found to have
a mean serum concentration of 20 g/mL. Further, the
incubation times were chosen based on previous experi-
ments, where marked differences in transcription rates
of the GHR/GHBP gene were seen at these times [29]. In
addition, maximum internalization of growth hormone is
reported after 2 hours, whereas hormone accumulation
in the nucleus was saturated after 1 hour [30]. Each ex-
periment was repeated eight times. Moreover, in order
to determine the effect on types I and IV collagen, IGF-I,
and IGFBP-1, the cells were incubated over a period of
72 hours.
RNA extraction
RNA was extracted as previously described [29], using
the acid guanidium thiocyanate-phenol-chloroform method
[31]. The RNA concentration was measured by absorbance
at 260 nm using a double-beam spectrophotometer (UV
150-02, Shimadzu Corporation, Tokyo, Japan).
Construction of the internal control and synthesis of
internal control RNA
The plasmid for the preparation of synthetic internal
control RNA (cRNA) was constructed by inserting a
50 base pair (bp) fragment of the rat prolactin (PRL)
receptor DNA into a portion of the GHR cDNA, as
previously described [32]. Briefly, the subsequent chime-
ric plasmid of GHR was cleaved with EcoRV and EcoRI,
and a 545 bp fragment was obtained. This fragment was
subcloned into the SmaI-EcoRI sites of bluescript SK 
(Stratagene Cloning System, San Diego, CA, USA). Fol-
lowing digestion with SalI, the chimeric GHR construct
served as a template for in vivo transcription by T7 RNA
polymerase to generate internal cRNA. The cRNA was
purified with phenol-chloroform extraction and subse-
quently by oligo (deoxythymidine) chromatography. The
absolute number of cRNA molecules was calculated us-
ing spectrophotometric absorbance at 260 nm, the molec-
ular weight of cRNA molecule (216,600 g/mol) and Avo-
gadro’s number.
Oligonucleotide primers used for amplification
Oligonucleotide primers were purchased from Mycro-
synth, Balgach, Switzerland. The sense primer was 5-CC
CTATATTGACAACATCAGTTCC-3; nucleotide 624
to 647 (exon 7) [33] and the antisense primer was 5-TT
CCCTTCCTTGAGGAGATCTGG-3 nucleotide 931
to 954 (exon 9) [33].
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cDNA synthesis and polymerase chain reaction
(PCR) amplification
Four micrograms of total RNA and 2.0  106 mole-
cules of internal control were reverse transcribed (RT)
with 200 U Moloney murine leukemia virus reverse tran-
scriptase (RT-M-MLV, Gibco BRL, Life Technologies,
Basel, Switzerland) primed with 1 g oligo (deoxythymi-
dine)12-18 primer (Roche, Rotkreuz, Switzerland). The RT
reaction was carried out in 50 L (total volume) RT-
buffer (50 mmol/L KCl, 5 mmol/L Mg2Cl, and 20 mmol/L
Tris-HCl, pH 8.3), 200mol/L deoxy-nucleotide-triphos-
phate (NTPs), 25 pmol sense and antisense primers, 5 L
of 50% formamide, 1  106 cpm 32P-end-labeled sense
primer of the GHR, and 1.5 U Ampli-Taq-DNA (Perkin-
Elmer, Rotkreuz, Switzerland). Sense primer was 5-end-
labeled with [gamma-32P] adenosine triphosphate (ATP)
(5000 Ci/mmol) (Amersham, Zu¨rich, Switzerland) us-
ing T4 polynucleotide kinase (Amersham). After the
initial denaturation at 95C for 11⁄2 minutes, the PCR
amplification was carried out in 24 cycles as follows:
denaturation 45 seconds at 94C, 11⁄2 minutes annealing at
55C, and 11⁄2 minutes of extension at 72C. Amplification
was completed with an additional extension step at 72C
for 10 minutes. PCR was performed in an AMS (Protocol
Thermal Cycler, AMS, Lugano, Switzerland).
Analysis of the PCR-amplified cDNA product
PCR products (21 L) were separated on 2% Meta-
phor gel (FMC, Bioproduct, BioConcept, Allschwill,
Switzerland) and stained with ethidium bromide. The
bands corresponding to each specific PCR product were
excised from the gels, and the amount of incorporated
radioactivity was determined in a 	-scintillation counter
(MR-300, Automatic Liquid Scintillation System, Kon-
tron, Zeiss AG, Zu¨rich, Switzerland). Radioactivity (counts
per minute) was plotted against the amount of template
(cRNA or target molecule). Identically sized gel pieces
of the negative control were excised at the position of
each positive band. The radioactivity of the negative
control values served as background.
Quantification of GHR mRNA
The radioactivity recovered from each gel slice was
plotted against either the amount of total RNA (nano-
grams) or cRNA (molecules). Previous studies have shown
that the two curves are parallel and exponential for both
cRNA and GHR/GHBP mRNA, suggesting that the
quantitative PCR is equally efficient for both controls
and target RNA without any competition that could in-
terfere with reliable quantification [32].
Nuclear run-on transcription
Nuclear run-on assays were performed as previously
described [29]. Briefly, nuclei were isolated from freshly
washed pellets of growth hormone–treated or untreated
human mesangial cells (T-HMC) and initiated transcripts
were allowed to extend in the presence of [
-32P] carba-
mylated protein (CTP) (3000 Ci/mmol, Perkin Elmer Life
Sciences, Hu¨nenberg, Switzerland). Each run-on probe
was hybridized with one of four identical filters dot-blotted
with 10g of each GHR clone,	-tubulin clone pD	-1SK1
DNA, and plasmid Bluescript SK DNA as a negative
control. After cross-linking of the DNA to the filters
(Hybond-C, Amersham), the filters were prehybridized
overnight at 42C. Run-on probe (6  107 cpm) synthe-
sized from treated or untreated T-HMC nuclei was added,
and the filters hybridized at 42C for 72 hours. The filters
were washed, dried, and autoradiographed. The strength
of each autoradiographic signal was determined by liquid
scintillation spectroscopy of excised filter pieces [29]. The
ratio of the counts corresponding to the GHR mRNA/
	-tubulin mRNA at time 3 hours without any growth hor-
mone added was arbitrarily set as 1.0 U, and other data
were expressed as GHR/GHBP run-on transcription units
using this base-line. 	-tubulin mRNA levels in T-HMCs
did not change as a result of growth hormone treatment
and could, therefore, be used to control for small varia-
tions in the quantity of RNA present in each sample
analyzed. The values obtained were checked against val-
ues obtained by scanning densitometry (Bio-Rad Model
620 Video Densitometer, Bio-Rad Laboratories, Hemel,
Hempstead, UK) of the autoradiograph, and were found
to correlate significantly (r, 0.93; P  0.001). In order to
analyze whether the changes in the rate of GHR/GHBP
gene transcription were dependent upon protein synthe-
sis, a second set of experiments was performed where
cycloheximide was added to the culture medium, at a
concentration of 10 g/mL, 30 minutes before either
growth hormone (25 and 500 ng/mL) and/or GHR-A
(12.5 and 500 ng/mL pegvisomant). In an additional set
of experiments, 22 kD growth hormone (25 ng/mL) was
combined with 12.5 ng/mL pegvisomant.
Determination of GHBP
GHBP was measured as described previously [34, 35],
using a minor modification of the method originally pub-
lished by Baumann et al [36]. Briefly, 100 L of medium
derived from the cell culture experiments was incubated
with 30,000 cpm 125I growth hormone for 45 minutes
at 37C, followed immediately by gel chromatography
(Sephacryl S200, column 1.8100 cm) at 4C using PBS.
Radioactivity in the eluate (1 mL fractions) was quanti-
fied and the portion of 125I growth hormone bound to
GHBP, with an apparent molecular weight of 85 K, was
calculated. The area of each peak was quantified using an
objective computer program (PeakFit, Jandel Scientific,
Erkrath, Germany). Chromatography on a long column
separates an additional binding protein of low affinity/
Meinhardt et al: GH effect on glomerular mesangial cells424
high capacity, and thereby reduces nonspecific binding
[37]. A separate chromatography step to determine non-
specific binding is therefore superfluous. Growth hormone
was determined in each medium sample by immunoradio-
metric assay (IRMA) (Medgenix, Brussels, Belgium).
The apparent binding of 125I growth hormone was cor-
rected for the growth hormone concentration in the sam-
ple, based on a displacement curve using increasing
amounts of unlabeled growth hormone [34].
Determination of collagen, IGF-I, and
IGFBP-1 synthesis
In order to test the impact of various concentrations
of growth hormone and growth hormone variants, as
well as pegviosmant (12.5, 25, 50, and 500 ng/mL) on
collagen types I and IV, IGF-I, and IGFBP-1 production,
the immortalized human glomerular mesangial cells were
incubated for 72 hours.
Each experiment was repeated five times. According
to the protocol provided by the company (Cedarlane,
Ltd., Hornby, Ontario Canada), 96-well flexible assay
microplates (Microtest III, Falcon, 3912, Fisher Scien-
tific, Wohlen, Switzerland) were coated with 200 L of
conditioned media and supernatant overnight at 4C.
Thereafter, the wells were washed three times for 5 min-
utes each in PBS at 20C. For determination of types I
and IV collagen, wells were incubated with 100 L, 1:200
dilution of a purified rabbit anti-human collagen types I
and IV (Cedarlane Ltd.) in PBS/3% bovine serum albu-
min (BSA) for 90 minutes at 20C under moderate stirring.
The wells were then washed three times for 5 minutes
each in PBS (at 20C) and incubated with 100 L, 1:100
dilution (PBS/3% BSA) of the secondary antibody-per-
oxidase conjugate (peroxidase-labeled rabbit anti-IgG;
Bio-Rad 75011, Bio-Rad Laboratoires AG, Rheinach,
Switzerland) for 90 minutes at 20C under moderate stir-
ring. Final detection was performed by incubating the wells
with 100 L of the chromogen solution [50 mL PBS, 118
mg phenol, 24 mg 4 aminoantipyrine (AMP), 30% H2O2
10 L added extemporaneously] for 90 minutes at 20C
and by assessing optical density of the stained reaction with
the spectrophotometer (Microplate reader, Thermomax,
Molecular Devices/Cytion SA, Epalinges, Switzerland)
at 450 nm. Regression analysis showed a linear detection
of types I and IV collagen between 20 and 45 ng/well
(r2  0.97) and 10 and 40 ng/well (r2  0.96), respectively.
All concentrations were normalized to 105 cells.
IGF-I in the supernatant was measured using the IGF-I
IRMA kit (Nichols Institute, San Juan Capistrano, CA,
USA). In order to ensure removal of IGFBPs and/or
IGFBP fragments, the samples were acidified to separate
the IGF-I and IGFBPs. Then, excess IGF-II was added
in the assay to block the IGFBP binding sites from re-
combining with the released IGF-I [38, 39]. Intra-assay
and interassay coefficient of variance was at 5 ng/mL
5.8% and 9.7%, respectively. IGBP-1-enzyme-linked im-
munosorbent assay (ELISA) was performed according
to the kit instructions of the company (IBL, Hamburg,
Germany; http://www.IBL-Hamburg.com). Intra-assay
and interassay coefficient of variance was at 3 ng/mL
3.6% and 8.1%, respectively.
Statistical analysis
Statistical differences among experimental groups
were determined by Student unpaired two-tailed t test.
The interassay coefficient of variation (CV) for the quan-
tification experiments and the run-on transcription was
6% and 8%, respectively. Values of P 0.05 were consid-




T-HMC were cultured in the presence of different
forms of growth hormone (22 kD, 20 kD) and of pegviso-
mant at variable concentrations. By using quantitative
RT-PCR, the abundance of GHR/GHBP transcripts was
measured at the beginning of the experiments as well as
after 0, 1, 3, and 6 hours. The overall data of the growth
hormone experiments performed are summarized in Ta-
ble 1 and Figure 1.
Effect of addition of 22 kD recombinant human growth
hormone. A dose-dependent increase in GHR/GHBP
gene expression was seen when physiologic doses of 12.5
and 25 ng/mL growth hormone were added to the culture
medium (Table 1 and Fig. 1A). In contrast, already the
treatment with a concentration of 50 ng/mL growth hor-
mone resulted in a significant (P  0.001) decrease of
GHR/GHBP mRNA expression, which was observed
during the first 3 hours of the assay. After 6 hours, the
level of expression increased, closely approximating the
1-hour level (Fig. 1A and Table 1). However, the 6-hour
level of GHR/GHBP expression was still significantly
decreased (P 0.01) when compared to the 0-hour level.
When a supraphysiologic concentration of 500 ng/mL
growth hormone was given to the T-HMCs, a constant and
significant (P  0.001) decrease of GHR (GHR/GHBP)
mRNA molecules given as number of molecules 106/g
total RNA was observed in the first 3 hours of the assay
and expression remained constantly decreased for the
duration of the experiments (3 hours to 6 hours) (Fig.
1A and Table 1).
Effect of addition of 20 kD recombinant human growth
hormone. The data obtained did not show any significant
difference to the results obtained in the experiments where
22 kD growth hormone was used (Table 1, Fig. 1A).
Effect of addition of the GHR antagonist “pegvisomant.”
The addition of any dose of pegvisomant (12.5 ng/mL,
25 ng/mL, 50 ng/mL, and 500 ng/mL, as well as 20 g/mL)
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Table 1. Number of growth hormone receptor (GHR) mRNA molecules in TSV40 cells using quantitative polymerase chain reaction (PCR)
GHR/GHBP mRNA (106 molecules/g total RNA)
Incubation times
0 hour P value 1 hour P value 3 hours P value 6 hours
22 kD growth hormone
0 ng/mL 1.070.02 0.001 0.920.01 0.001 0.800.02 0.01 0.720.01
12.5 ng/mL 1.030.02 0.01 1.090.02 NS 1.100.02 NS 1.090.01
25 ng/mL 1.090.02 0.01 1.160.02 0.01 1.270.03 0.01 1.370.02
50 ng/mL 1.110.02 0.01 0.990.03 0.01 0.830.04 0.001 0.980.03
500 ng/mL 1.140.02 0.001 0.860.02 0.001 0.540.01 NS 0.530.02
20 kD growth hormone
12.5 ng/mL 1.020.02 NS 1.090.02 NS 1.110.02 NS 1.100.02
25 ng/mL 1.040.01 0.001 1.180.02 0.01 1.270.03 NS 1.300.03
50 ng/mL 1.080.02 0.01 1.010.02 0.001 0.820.03 NS 0.910.03
500 ng/mL 1.120.02 0.001 0.730.02 0.001 0.560.03 0.01 0.460.02
GHR-A (pegvisomant)
12.5 ng/mL 1.030.01 0.001 0.700.03 NS 0.670.02 NS 0.640.03
25 ng/mL 1.010.02 0.001 0.740.02 0.01 0.650.03 0.01 0.580.02
50 ng/mL 1.060.02 0.001 0.720.01 0.001 0.600.02 0.01 0.520.02
500 ng/mL 1.070.02 0.001 0.710.02 0.01 0.640.01 NS 0.610.02
20 g/mL 1.110.01 0.001 0.760.02 0.01 0.670.01 NS 0.630.01
GHR-A (pegvisomant) 22 kD growth hormone
12.5 ng/mL 12.5 ng/mL 1.010.01 0.001 0.730.03 NS 0.710.02 NS 0.680.03
12.5 ng/mL 25 ng/mL 1.040.01 0.001 0.780.02 NS 0.720.03 0.01 0.640.02
12.5 ng/mL 50 ng/mL 1.050.01 0.001 0.740.02 0.01 0.670.02 0.01 0.560.02
12.5 ng/mL 500 ng/mL 1.080.02 0.001 0.790.02 0.001 0.530.01 0.01 0.470.02
GHBP is growth hormone binding protein.
Fig. 1. Quantitative reverse transcription-poly-
merase chain reaction (RT-PCR) amplification.
Time course of effects of different concentra-
tions of 22 kD and 20 kD growth hormone (GH)
(A ), pegvisomant (B2036-PEG) (B ) as well
as the inhibitory effect of B2036-PEG (GHR-A)
(C ) on GHR/GHBP gene expression [growth
hormone receptor/growth hormone binding
protein (GHR/GHBP) mRNA] in a human
glomerular mesangial cell line (T-HMC) is de-
picted. The cells were cultured in serum-free
hormonally defined medium and were har-
vested for RNA extraction at 0, 1, 3, and 6
hours after the addition of either 22 kD, 20 kD
growth hormone, pegvisomant, or the variable
concentrations of growth hormones and pegvi-
somant. Values plotted are means of values ob-
tained from eight individual cultures (Table 1).
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Fig. 2. Run-on experiments. Effects of differ-
ent concentrations of 22 kD growth hormone
(GH) (0, 25, and 500 ng/mL) or pegvisomant
(B2036-PEG) (12.5 and 500 ng/mL) following
3 hours incubation time on transcription of
GHR/GHBP gene in human glomerular mes-
angial cells (T-HMC) are shown. The auto-
radiographic signals were quantified by liquid
scintillation counting of filter pieces as de-
scribed in the Methods section. The ratio ob-
tained with growth hormone receptor/growth
hormone binding protein (GHR/GHBP) tar-
get DNA to that obtained with the 	-tubulin
target DNA was calculated for each set of
culture conditions. This ratio was arbitrarily set
at 1 U for untreated T-HMC cells, and other
values were adjusted accordingly and plotted.
Values shown are means of values obtained
in eight parallel experiments from eight indi-
vidual cultures. Symbols are: () without cyclo-
heximide; ( ) with cycloheximide. The lines
above the bar indicate SEM.
did not augment GHR/GHBP expression over the time
period studied (Table 1 and Fig. 1B). Most interestingly,
the different levels reached were even significantly (P 
0.01) decreased in comparison to the data obtained in
the experiments where no growth hormone at all was
added (Table 1). Obviously the GHR/GHBP expression
rates were significantly different (P  0.001) at all times
and concentrations when compared with the expression
levels obtained in the experiments where either 22 kD
or 20 kD growth hormone was used (Table 1).
To study the antagonistic impact of pegvisomant on
the GHR expression, variable concentrations of the 22
kD growth hormone form were combined with 12.5
ng/mL pegvisomant and added to the cell culture. Even
the lowest concentration of pegvisomant (12.5 ng/mL)
used was able to completely and significantly suppress
the changes in GHR/GHBP gene expression (Table 1
and Fig. 1C).
Run-on assay
By performing nuclear run-on experiments, we also
examined the question of whether the changes in GHR/
GHBP gene transcription levels were real, and therefore
the results of a changed rate of transcription. T-HMCs
were cultured under the same conditions as the cells used
for RNA quantification for 3 hours in the presence of
different concentrations of growth hormone (25 ng/mL
and 500 ng/mL) and pegvisomant (12.5 ng/mL and 500
ng/mL). The doses of 25 ng/mL and 500 ng/mL of growth
hormone were chosen because the most significant differ-
ences in transcription rate could be expected here. In
addition, nuclei were prepared from freshly isolated cells
and radiolabeled run-on probes were synthesized and
hybridized to filters carrying GHR/GHBP and 	-tubulin
cDNA fragments (Fig. 2). The data were consistent with
the results obtained in the quantitative RT-PCR experi-
ments. In order to analyze whether the changes in the
rate of GHR/GHBP gene transcription depend on new
protein synthesis, cycloheximide (10 g/mL) was added
to the culture medium 30 minutes before the growth
hormone. The levels of the run-on transcripts remained
unchanged in all the experiments (Fig. 2). This indicates
that the regulating effects of growth hormone on the
GHR/GHBP gene transcription were dependent, at least
partly, on preexisting factors and did not require protein
synthesis.
Determination of GHBP levels in the culture medium
In order to define whether changes in GHR gene ex-
pression might be reflected in GHBP levels following
the incubation with 22 kD growth hormone and pegviso-
mant, GHBP levels were determined in the cell culture
medium using the same experimental procedure as for
the RNA quantification. The binding of 125I growth hor-
mone, after correction for the amount of growth hor-
mone present in the culture medium, is presented as
corrected percentage binding and values shown are indi-
cated as mean  SD. As shown in Figure 3, binding of
125I growth hormone significantly (P  0.001) increased
following the addition of more than 12.5 ng/mL growth
hormone. The addition of pegvisomant in variable con-
centrations (12.5, 25, 50, and 500 ng/mL), however, did
not present any significant changes of GHBP measured
when compared with the experiments where neither
growth hormone nor pegvisomant was added.
Determination of types I and IV collagen, IGF-I and
IGFBP-1 levels in the culture medium
In order to further analyze the impact of the various
growth hormone and GHR-A concentrations on mesan-
gial cells, the secreted quantity of types I and type IV
collagen as well as IGF-I and IGFBP-1 was measured
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Fig. 3. Different concentrations (0, 12.5, 25, 25, 50, and 500 ng/mL) of
22 kD as well as pegvisonmant (B2036-PEG) were separately added
to the culture medium as described in the Methods section. Thereafter,
growth hormone binding protein (GHBP) was measured following 2
hours of incubation. Values plotted are means of values obtained in
eight parallel experiments from eight individual cultures.
in the supernatant of the cell culture following 72 hours
of incubation (Table 2). Most important, there was a
significant, growth hormone dose-dependent increase of
the type IV collagen concentration in the medium,
whereas type I collagen only increased following incuba-
tion at high growth hormone concentrations (500 ng/
mL). This stimulatory effect was not seen after the incu-
bation with pegvisomant, types I and IV collagen did
not change at all. Further, even the addition of the lowest
dose of pegvisomant (12.5 ng/mL) to the cell culture
medium blocked the stimulatory effect of 500 ng/mL 22
kD growth hormone on collagen secretion (Table 2).
Moreover, IGF-I concentration in the supernatant was
not measurable when the cells were exposed to no or
low growth hormone concentration (12.5 ng/mL) or fol-
lowing the pegvisomant stimulation. The addition of in-
creasing growth hormone concentrations to the cell cul-
ture medium, however, resulted in an increase in the
secreted IGF-I level. Further, IGFBP-1 concentration
in the supernatant after 72-hour cell culture incubation
increased parallel to the IGF-I levels.
DISCUSSION
Although recent evidence suggests that constitutive
autocrine secretion of IGF-I as well as activation of its
signaling pathways in the kidney participate in the devel-
opment and progression of glomerulosclerosis [1, 6, 40],
previous data derived from mice transgenic for IGF-I
demonstrated renal and glomerular hypertrophy but no
glomerulosclerosis. Mice transgenic for growth hormone,
however, developed severe glomerulosclerosis, leading
to uraemia and eventually death [13]. Therefore, based
on many reports it is postulated that growth hormone
may play an important role in the development of glo-
merular sclerosis in any clinical situation where increased
levels of growth hormone are found [1–3, 8–10, 13, 14,
16–19, 21, 22]. This notion is further strengthened by
data obtained from studies in which the development of
glomerulosclerosis was prevented in mice transgenic for
a growth hormone antagonist [22, 41]. Furthermore, it
was shown that the overexpression of a growth hormone
antagonist, which suppressed endogenous growth hor-
mone, also prevented the development of glomeruloscle-
rosis in mice presenting with uncontrolled hyperglycae-
mia [41]. However, the mechanisms that cause or prevent
the histologic lesions in glomeruli are still not fully under-
stood. It has been suggested that the absence of glomeru-
losclerosis where there is a lack of functional growth
hormone may be due to the interruption of a growth
hormone–mediated increase in glomerular type IV colla-
gen and laminin synthesis as well as the absence of its
accumulation [8].
As mesangial cells are most important and central to
the physiology and pathophysiology of the glomerulus,
the aim of our studies was to analyze the impact of
different growth hormone variants and pegvisomant at
variable concentrations, on the GHR (GHR/GHBP)
gene transcription in stable cell lines of T-SV40 immor-
talized glomerular mesangial cells [26, 42]. Human
growth hormone consists of several structural modified
isoforms that have been detected in the pituitary gland
and the placenta as well as in the circulation [43–45].
The major physiologic component of pituitary gland–
secreted growth hormone (about 85%) is a single-chain
polypeptide of 191 amino acids with a molecular mass
of 22 kD. Using the 22 kD growth hormone exclusion
assay, an immunomagnetic extraction method for mea-
surement of non-22 kD growth hormone isoforms in
human blood [46], an average proportion of 8.1% (range,
3.2% to 13.9%) of non-22 kD growth hormone isoforms
in normal prepubertal children were reported, of which
the 20 kD growth hormone variant represents the major
proportion [46]. Therefore, in our studies the 20 kD
variant of growth hormone, which represents a growth
hormone form with deletion of amino acids 32 to 46 of
the regular amino acid sequence, was examined as well.
As previously reported in a hepatoma cell line, the 22 kD
and the 20 kD growth hormone forms showed similar
effects on GHR/GHBP gene regulation. In these experi-
ments using human glomerular mesangial cells, there
was a constant and dose-dependent increase of growth
hormone/GHBP mRNA concentration whenever physi-
ologic doses of growth hormone (12.5 ng/mL and 25 ng/mL)
were used. At supraphysiologic doses of growth hormone
(50 ng/mL and 500 ng/mL) a dose-dependent and statisti-
cally significant down-regulation of the GHR/GHBP
transcription was found (Table 1 and Fig. 1A). This find-
ing might, partly, explain the reduced IGF-I mRNA pro-
duction in the kidney as reported in diabetes mellitus,
possibly caused by a specific growth hormone resistance
[9, 11]. Importantly, all these data were confirmed using
run-on experiments. This fact confirms that the data ob-
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Table 2. Secreted amount of type I and IV collagen, IGF-I and IGBP-1 into the culture medium
Collagen type IV Collagen type I IGF-I ng/mL IGFBP-1 ng/mL
ng/well per 105 cells ng/well per 105 cells per 105 cells per 105 cells
22 kD growth hormome
0 ng/mL 14.32 26.76 Not measurable Not measurable
12.5 ng/mL 23.84a 29.35 1.31 Not measurable
25 ng/mL 33.73b 26.26 2.51 3.11
50 ng/mL 36.65b 31.17 12.34c 7.82b
500 ng/mL 38.57b 49.25a 15.85c 8.42b
20 kD growth hormone
12.5 ng/mL 22.96a 23.96 Not measurable Not measurable
25 ng/mL 34.45b 28.43 2.11 3.91
50 ng/mL 38.75b 25.27 9.82b 5.21a
500 ng/mL 40.96b 36.78a 13.41c 9.51b
GHR-A
12.5 ng/mL 11.84 24.85 Not measurable Not measurable
25 ng/mL 13.15 29.35 Not measurable Not measurable
50 ng/mL 14.54 32.09 Not measurable Not measurable
500 ng/mL 13.72 29.37 Not measurable Not measurable
20 g/mL 12.35 23.77 Not measurable Not measurable
GHR-A 22 kD growth hormone
12.5 ng/mL 500 ng/mL 16.15 27.36 Not measurable Not measurable




tained in the quantitative PCR experiments are real. As
the addition of cycloheximide to the culture medium did
not significantly change the transcription rate during the
run-on experiment, it is clear that the synthesis of new
enzymes is not necessary. Furthermore, like other poly-
peptide hormones, growth hormone exerts its effect by
binding to a specific, high-affinity cell surface protein,
the GHR. In addition, a specific serum binding protein
for growth hormone (GHBP), with high affinity and low
capacity for growth hormone, has been characterized in
humans [47–49] and several other mammalian species,
including rabbit [50], mouse [51], rat [52], pig, and dog
[53]. The amino acid sequence of this GHBP has been
shown to be identical to the extracellular domain of the
liver membrane GHR [47]. In rats and mice, GHR and
GHBP are encoded by two distinct mRNAs generated
by alternative splicing of a single primary transcript
[54, 55]. In mammals, however, there is evidence that
GHBP is produced by specific proteolysis of the GHR
[56–58]. Therefore, as in our experiments human glomer-
ular mesangial cell were studied, we were able to obtain
information on both GHR and GHBP transcription. In
order to study the GHBP formation, the GHBP was
measured in the cell culture medium. These analyses
were performed to study the possible impact of the vari-
able growth hormone forms on the regulated GHBP
formation/release under these different culture circum-
stances. Interestingly, there was a constant increase of
GHBP found in the cell culture medium. This fact may be
because the cells are preventing themselves from being
overfloated by masses of growth hormone. Similar data
have already been found and reported in liver cells [29].
In order to obtaine more detailed information about
the effects of growth hormone on the regulation of GHR/
GHBP transcription, a GHR antagonist with enhanced
affinity for the human GHR (pegvisomant) was studied
at different concentrations. Pegvisomant is a member of
a GHR antagonist family recently developed for the
human GHR that has been successfully used in acrome-
galic patients [59]. As the mean serum concentration of
pegvisomant in the patients treated with a daily dose of
20 mg was about 20 g/mL, this additional concentration
was used in our experiments [59]. The findings were
most impressive. Pegvisomant was able to inhibit GHR/
GHBP gene transcription at any concentration used.
These data are consistent with previously reported data
in diabetic mice [9, 12, 60], but the major new finding
of the present study is that a GHR-A directly inhibits
GHR/GHBP gene transcription at the cellular level in
human mesangial cells.
As short-term experiments (incubation up to 6 hours)
to test the impact of these various growth hormone and
pegvisomant concentrations on the amount of types I
and IV collagen, IGF-I, and IGFBP-1 secreted showed
no effect, cell culture studies were expanded for 72 hours
and the supernatant was analyzed thereafter. Impor-
tantly, after this prolonged incubation, there was an in-
crease in collagen secretion into the cell culture medium,
which paralleled the increase in growth hormone concen-
tration added to the cell culture medium. Pegvisomant,
however, did not demonstrate any secretory effect and
inhibited the effect of growth hormone (500 ng/mL) on
collagen secretion into the cell culture medium at even
the lowest dose (12.5 ng/mL). Further, on increasing
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growth hormone concentration a significant increase in
IGF-I and IGFBP-1 concentration in the supernatant
following incubation for 72 hours could be found. These
data are in agreement with the hypothesis that IGFBP
may prevent the degradation of collagen [61].
CONCLUSION
We present data showing that 22 kD and 20 kD growth
hormone have the same bioactivity and a specific and
direct impact on GHR/GHPB gene transcription, and
that pegvisomant is a potent GHR antagonist not only
in liver cells but also in human glomerular mesangial
cells. In addition, although the GHR/GHBP gene tran-
scription is down-regulated by supraphysiologic concen-
trations of growth hormone, this effect was not found
when GHBP levels were measured in the cell culture
medium. This finding may reflect a self-inhibitory effect
of growth hormone on the level of GHR/GHBP gene
transcription but not on the regulation of the shedding
of GHBP and may, therefore, be of physiologic interest.
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